CELLECT BIOTECH/S (NASDAQ:APOP) shares rose 10.2% during trading on Monday . The stock traded as high as $0.54 and last traded at $0.54, approximately 147,429 shares traded hands during mid-day trading. A decline of 44% from the average daily volume of 265,437 shares. The stock had previously closed at $0.49.

Separately, ValuEngine upgraded shares of CELLECT BIOTECH/S from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

The business’s fifty day moving average is $0.53 and its 200 day moving average is $0.81. The company has a current ratio of 6.01, a quick ratio of 6.01 and a debt-to-equity ratio of 0.04.

CELLECT BIOTECH/S (NASDAQ:APOP) last posted its quarterly earnings data on Tuesday, May 21st. The company reported ($0.16) earnings per share (EPS) for the quarter.

An institutional investor recently bought a new position in CELLECT BIOTECH/S stock. Wedbush Securities Inc. bought a new position in shares of CELLECT BIOTECH/S (NASDAQ:APOP) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $66,000. Wedbush Securities Inc. owned 1.19% of CELLECT BIOTECH/S as of its most recent SEC filing. Institutional investors and hedge funds own 7.22% of the company’s stock.


Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Recommended Story: What is a growth and income fund?

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.